The UAB P30 Research and Translation Core Center consolidates a large number of externally funded cystic fibrosis (CF) research programs on our campus, building an innovative environment to pursue, advance, and train in CF-related science. During the last funding period, the P30 made robust and important contributions to multiple UAB laboratories of our Research Base of over 70 investigators pursuing research relevant to CFTR modulation, CF pathogenesis, and therapeutic translation. By virtue of the NIH Center, translational research at our Institution has greatly accelerated in the past five years, as has the breadth of investigators. The richness of CF basic science at UAB has grown in parallel with this translational expansion, providing numerous opportunities to exploit in the next funding period, and we have modified the structure of the Center accordingly to take advantage of these opportunities. The P30 Center has allowed investigators at UAB and collaborating sites to improve understanding of CF disease mechanism and has furnished novel opportunities to aggressively apply this information towards experimental therapeutics. This NIH Center includes three Biomedical Research Cores that help to organize efforts of CF faculty towards the common and essential goal of helping individuals with CF and to train the next generation of CF leaders. The Cores include: Core A: Cell Model and Assay Core (B Woodworth and GM Solomon, Co-PIs); Core B: Animal Models Core (DM Bedwell, PI); and Core C: Clinical and Translational Core (SM Rowe and A Gaggar, Co-PIs). Each Core provides leading-edge assays, specialized reagents and techniques, and valued expertise. The P30 has also engaged new investigators through a Pilot and Feasibility mechanism integral to Center vitality and has a tight integration with the UAB Center for Clinical and Translational Science, enabling a robust training environment. In addition to providing a platform from which junior and senior scientists are brought into the field, Pilot Projects serve as a means of rapidly testing exciting advances, particularly from the perspective of clinical translation. Two Pilot and Feasibility Projects are proposed: Project 1: V Thannickal, PI. ?Mucus Viscoelasticity is Mediated by Oxidase Enzymes through Oxidative Protein Crosslinking?; and Project 2: J Campos-Gomez, PI. ?Engineered PF Phage to Treat Pseudomonas aeruginosa Biofilm Infections?, capitalizing on the next era of innovative opportunities to transform the disease. Through these scientific initiatives, the P30 has added value to a collaborative environment for CF research at our Institution, and is well-positioned to continue in this capacity in the future, with a major focus on therapeutic translation.

Public Health Relevance

The UAB Gregory Fleming James Cystic Fibrosis Research Center (CF Center), supported by the NIH P30, is dedicated to advancing high-impact, multidisciplinary research that heightens the field's understanding of CF disease mechanisms and accelerates the development of treatments for availability to CF patients. Success toward this goal is made possible by the Center's well-funded Research Base, robust and cutting-edge Biomedical Research Core resources and services, effective Administrative Core offerings, and successful Pilot & Feasibility and Enrichment Programs, in addition its strong commitment from the University and its role as a valuable local, national, and international clinical hub. Progress is measured by the output of innovative contributions, scientific discovery, and clinical translation designed to improve the lives of patients with the disease.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1)
Program Officer
Eggerman, Thomas L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Alabama Birmingham
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Cho, Do-Yeon; Lim, Dong-Jin; Mackey, Calvin et al. (2018) l-Methionine anti-biofilm activity against Pseudomonas aeruginosa is enhanced by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor. Int Forum Allergy Rhinol 8:577-583
Guimbellot, Jennifer S; Acosta, Edward P; Rowe, Steven M (2018) Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer. Pediatr Pulmonol 53:E6-E8
Solomon, George M; Bronsveld, Inez; Hayes, Kathryn et al. (2018) Standardized Measurement of Nasal Membrane Transepithelial Potential Difference (NPD). J Vis Exp :
Reeves, Emer P; O'Dwyer, Ciara A; Dunlea, Danielle M et al. (2018) Ataluren, a New Therapeutic for Alpha-1 Antitrypsin-Deficient Individuals with Nonsense Mutations. Am J Respir Crit Care Med 198:1099-1102
McCormick, Lydia L; Phillips, Scott E; Kaza, Niroop et al. (2018) Maternal Smoking Induces Acquired CFTR Dysfunction in Neonatal Rats. Am J Respir Crit Care Med 198:672-674
Duncan, Gregg A; Kim, Namho; Colon-Cortes, Yanerys et al. (2018) An Adeno-Associated Viral Vector Capable of Penetrating the Mucus Barrier to Inhaled Gene Therapy. Mol Ther Methods Clin Dev 9:296-304
Gelfond, Daniel; Heltshe, Sonya L; Skalland, Michelle et al. (2018) Pancreatic Enzyme Replacement Therapy Use in Infants With Cystic Fibrosis Diagnosed by Newborn Screening. J Pediatr Gastroenterol Nutr 66:657-663
Birket, Susan E; Davis, Joy M; Fernandez, Courtney M et al. (2018) Development of an airway mucus defect in the cystic fibrosis rat. JCI Insight 3:
Shei, Ren-Jay; Peabody, Jacelyn E; Kaza, Niroop et al. (2018) The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis. Curr Opin Pharmacol 43:152-165
Gebert, Magdalena; Bartoszewska, Sylwia; Janaszak-Jasiecka, Anna et al. (2018) PIWI proteins contribute to apoptosis during the UPR in human airway epithelial cells. Sci Rep 8:16431

Showing the most recent 10 out of 175 publications